TITLE

Noteworthy

PUB. DATE
June 2008
SOURCE
Pharmaceutical Representative;Jun2008, Vol. 38 Issue 6, p15
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article presents several research related to pharmaceuticals in the U.S. People with bigger brains are resistant to Alzheimer's disease, according to a study presented at the 60th annual meeting of the American Academy of Neurology. Results of the Eliminating Disparities in Clinical Trials (EDICT) Project suggested the improvement of U.S. clinical trials. A published research showed an increase in the rate of hospitalized children.
ACCESSION #
32429552

 

Related Articles

  • Detecting and Preventing AD Focus of Products in Pipeline. Winter, Peter // BioWorld Insight;10/21/2013, Vol. 21 Issue 43, p1 

    The author reflects on the issue related to the Alzheimer's disease (AD) and and its primary hurdles to combating it. Sponsored by the Pharmaceutical Research and Manufacturers of America, the Alzheimer's Association and the Alzheimer's Drug Discovery Foundation. He states that the research will...

  • Alzhemed: A Potential Treatment for Alzheimer's Disease. Aisen, Paul S.; Gauthier, Serge; Vellas, Bruno; Briand, Richard; Saumier, Daniel; Laurin, Julie; Garceau, Denis // Current Alzheimer Research;Oct2007, Vol. 4 Issue 4, p473 

    As a potential disease-modifying treatment for AD, Alzhemed (tramiprosate) is a compound that binds to soluble amyloid-beta peptide (A�) and inhibits the formation of neurotoxic aggregates that lead to amyloid plaque deposition in the brain. The safety, tolerability, and pharmacodynamic...

  • Memapsin 2 (Beta-Secretase) Inhibitor Drug, between Fantasy and Reality. Ghosh, Arun K.; Bilcer, Geoffrey; Hong, Lin; Koelsch, Gerald; Tang, Jordan // Current Alzheimer Research;Oct2007, Vol. 4 Issue 4, p418 

    A major strategy for the development of a disease-modifying therapy against Alzheimer's disease is pharmacological intervention designed to reduce levels of �-amyloid in the brain. Among various ways of reducing �-amyloid production, the inhibition of �-secretase (memapsin 2,...

  • Principles of age-related changes in the canine and feline brain. Papaioannou, Nikolaos // Acta Veterinaria;Mar2014, Vol. 64 Issue 1, p1 

    In the aged dog and cat, especially dog, a cognitive decline develops naturally in many different domains, but at the same time it also exhibits human-like individual variability in the aging process. In the aging dog and cat brain lesions develop spontaneously. Dogs share some morphological...

  • Alzheimer's Advances Depend on Early Diagnosis.  // Applied Clinical Trials;Apr2011, Vol. 20 Issue 4, p14 

    The article discusses the treatment for Alzheimer's disease and offers information on various clinical trials worldwide with relevance to its medications in 2010 and 2011. It notes that the Pharmaceutical Research and Manufacturers of America (PhRMA) has reported that there are five marketed...

  • Pfizer and Eisai hit by academic research on Aricept.  // PharmaWatch: CNS;August 2004, Vol. 3 Issue 8, p7 

    Researchers at the University of Birmingham in the UK have concluded, after a five-year investigation, that the Altzheimer's drug Aricept, co-marketed by Pfizer Inc. and Eisai, has no beneficial effect. Eisai share value fell 3.43% after the results were released. Professor Richard Gray,...

  • Learning from failure.  // Nature Reviews Drug Discovery;Jul2010, Vol. 9 Issue 7, p499 

    The launch of a new initiative to share data from failed clinical trials of investigational drugs for Alzheimer's disease provides both a promising opportunity to improve drug development in this field, as well as a novel mechanism to learn more from negative trials in general.

  • Is Tau How? GMS Bets $31.5M On Alzheimer's Phase III Effort. Osborne, Randy // BioWorld Today;11/21/2012, Vol. 23 Issue 227, p1 

    The article focuses on Phase III trials, funded by Genting Management (Singapore) Pte. Ltd., that focus on therapies for Alzheimer's disease. It notes the commencement of trials with tau aggregation inhibitor LMTX which aims to stop the binding of normal tau protein to neuronal waste products....

  • 2012 in reflection. Tse, Man Tsuey; Kirkpatrick, Peter // Nature Reviews Drug Discovery;Jan2013, Vol. 12 Issue 1, p8 

    The article offers information related to drug development and research in 2012. It mentions that the U.S. Prescription Drug User Fee Act (PDUFA) that was authorized in July 2012 is concern of developing breakthrough products. It explores the launch of the Innovative Medicines Initiative (IMI)...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics